Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
about
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trialsComparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complexPharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureusComparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzaeComparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess.Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patientsBactericidal activity and postantibiotic effect of levofloxacin against anaerobes.Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial speciesSafety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patientsPharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens.Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationRecombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review.Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococciPharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjectsSteady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.The new fluoroquinolones: A critical reviewPharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy VolunteersSetting and revising antibacterial susceptibility breakpoints.Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects (pagesLevofloxacin pharmacokinetics in adult cystic fibrosis.Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns.A population pharmacokinetic analysis of the penetration of the prostate by levofloxacinDouble-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.Reducing antibacterial development risk for GSK1322322 by exploring potential human dose regimens in nonclinical efficacy studies using immunocompetent rats.Identifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach.Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureusTemporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.Pharmacokinetics of second-line anti-tuberculosis drugs in children with multidrug-resistant tuberculosis in India.
P2860
Q24655866-255D4ECC-F2DC-4637-88E6-2A7471E4FF38Q28343858-B5DF2E49-397D-4AC3-992F-3E088948DE78Q33836597-651B8072-31C3-4EEB-89EA-A6A085B416C2Q33856741-E22FE2D6-B800-4254-A24E-02570F058668Q33976511-5F71DC7A-4DDB-423D-B57B-E8FF01DC0C6DQ33977737-FEE1E392-9E7D-4DAF-AD8B-AD9AEFC82F0CQ33977925-8D73344D-2C97-44EC-9181-9A7F9F880412Q33979516-C6E5BE81-F112-49A0-B0EF-CE4031AF3491Q33980661-7EBB0EC8-62D9-4FC5-BF3E-F1D4F082EDE8Q33981082-B1DD9425-AFA1-461D-93E1-F88599EB5FAEQ33982566-B3B9818B-093D-41FC-8E51-E8E955CEA852Q33983228-B67F3809-3899-47FF-A268-5B75FA54E330Q34057534-AA89F931-19DC-47EE-8E15-4521FECA6F3DQ34098582-2563E722-93E3-4D01-A887-A76D00FC12BAQ34108623-D07D91CD-8680-455F-98A9-9E4590132A93Q34188814-B8F31B91-FEF9-42D1-816F-F05E53B78A0AQ34303179-E07A423F-27A0-4346-966F-3AD43AAD1F09Q34551560-03274717-E341-4848-9875-93299C1B65F3Q35005511-69661A1B-39E5-44FD-9C91-99437B9D97ECQ35065775-EAD0CCA0-47A6-4358-8BED-4CFB5411E3DAQ35127882-B2DA646A-EBDB-4CC2-9658-7C4609F13D72Q35138534-40D49B6D-1EF8-41BB-BDAA-F52F88D71C72Q35166134-89E2DBEB-B2F5-4A1C-A155-BB5672BC4139Q35191364-208C105B-F3F6-48E5-9DB1-5A7BDCAC95C6Q35649595-EE1789AD-4E4E-4E89-9EC9-51EEE1975211Q35860097-A7A2181B-D4AD-4F58-9E9D-56E6C286806CQ35913176-4117E7AA-3F83-44C4-B282-493873536DE1Q36017405-B3202189-BF0B-444F-A23A-88176AA88945Q36137356-3A07E979-1EDD-4527-9F69-6CFA44F61FFEQ37678156-18B80518-6F92-4C83-90DB-FF1358CA61C7Q37876071-B16CAE85-D294-44C1-9D28-0B8B3F412FF8Q39557455-039272CB-AE32-43F4-8CB9-EABE04B709F8Q39651272-0EC06B46-278C-4440-A8D7-AA443352F160Q39746394-3D228CD3-3835-416F-B204-CEED72E5004FQ40093553-A6D41F2B-9E51-408D-A978-5FCF9A269730Q40225657-1EE9E16B-D537-42ED-8265-7E875943FD46Q40903164-E1280CB0-CC4E-40DC-9F3D-CB0B24DE81ABQ41788804-D3639527-6646-4447-8DE0-51450493A468Q41899401-6380A41A-2ECD-439D-BFE6-274854E8A993Q49792011-899DAD73-7F0F-4D58-B2A8-8BB781E79B18
P2860
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Pharmacokinetic profile of lev ...... gram oral or intravenous doses
@en
Pharmacokinetic profile of lev ...... ram oral or intravenous doses.
@nl
type
label
Pharmacokinetic profile of lev ...... gram oral or intravenous doses
@en
Pharmacokinetic profile of lev ...... ram oral or intravenous doses.
@nl
prefLabel
Pharmacokinetic profile of lev ...... gram oral or intravenous doses
@en
Pharmacokinetic profile of lev ...... ram oral or intravenous doses.
@nl
P2093
P2860
P1476
Pharmacokinetic profile of lev ...... gram oral or intravenous doses
@en
P2093
Gisclon LG
Natarajan J
Williams RR
P2860
P304
P407
P577
1997-10-01T00:00:00Z